共 205 条
[1]
Ferrara N(2004)Vascular endothelial growth factor: basic science and clinical progress Endocr Rev. 25 581-611
[2]
Carmeliet P(2000)Angiogenesis in cancer and other diseases Nature. 407 249-257
[3]
Jain RK(2009)Aflibercept in epithelial ovarian carcinoma Future Oncol. 5 591-600
[4]
Moroney JW(2012)A preclinical and clinical review of aflibercept for the management of cancer Cancer Treat Rev. 38 484-493
[5]
Sood AK(2002)VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A. 99 11393-11398
[6]
Coleman RL(2011)Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma Proc Natl Acad Sci U S A. 108 3749-3754
[7]
Gaya A(2012)Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen Oncology (Williston Park) 26 842-3506
[8]
Tse V(2012)Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial J Clin Oncol. 30 3499-768
[9]
Holash J(2013)Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer Lancet Oncol. 14 760-2642
[10]
Davis S(2013)Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial Eur J Cancer. 49 2633-3647